| Objective:The purpose of this study is to objectively evaluate the clinical efficacy of jinghua wekang capsule combined with the four-way therapy in the treatment of chronic non-atrophic gastritis caused by helicobacter pylori infection in patients with syndrome differentiation of cold and heat in traditional Chinese medicine,from the aspects of clinical symptom improvement,Hp eradication rate and adverse reactions,so as to provide evidence for clinical application.Research methods:Into the object of this study is during January 2019 to December 2019,to the Digestive Department of Jiangsu Province hospital of Chinese medicine,both by gastroscope pathological diagnosis of chronic non-atrophic gastritis,and associated with helicobacter pylori infection without eradication therapy,in a word,TCM syndrome differentiation in line with the fever syndrome patients,according to the clinical time were randomly divided into treatment group and control group.The control group was treated with Bismuth quadruplicate(PPI+bismuth agent+2 antibiotics)according to the "fifth national consensus report on the management of helicobacter pylori infection"[1].The test group was treated with Jinghua weikang capsule on the basis of the control group,each time 160mg,3 times a day.Both groups took the drugs continuously for 14 days,and the breath test of 14C or 13C urea was conducted 4 weeks after drug withdrawal.According to the quantitative grading table,the TCM symptom scores of patients were recorded to objectively evaluate the effectiveness and safety of the research program.Research results:(1)General situation analysis:there was no significant difference in the distribution of age,gender,tobacco and alcohol history and family history between the two groups(P>0.05),suggesting comparability.(2)Hp eradication rate:there were 30 cases in both groups.Hp review showed that there were 5 cases of eradication losers in the experimental group with an eradication rate of 83.3%,and 10 cases of eradication losers in the control group with an eradication rate of 66.7%.Data analysis showed that P=0.136(>0.05).(3)Total effective rate of TCM syndromes:the total effective rate of the experimental group was 90.0%,and that of the control group was 66.7%.The difference was P<0.05,and the curative effect of the experimental group was more obvious than that of the control group.(4)Total score of TCM symptoms:there was no difference in the score of symptoms between the two groups before treatment(P>0.05),indicating comparability.In comparison,the scores of the two groups after treatment were reduced compared with those before treatment(P<0.05).The score difference between the experimental group and the control group was statistically significant(P<0.05),and the efficacy of the experimental group was better than that of the control group.(5)Score of single symptom:compared within the group,the main symptoms(epigastric area,stomachache,hunger and intolerance)and secondary symptoms(stomach cold and fear of cold or noise,dry mouth and bitter mouth,and loose stools)achieved results after treatment.Comparison of the difference between groups showed that the experimental group was better than the control group in improving the symptoms of epigastric swelling,stomachache,cold or noisy stomach,dry mouth and bitter mouth,stagnation and discomfort in stool(P<0.05).There was no statistically significant difference between the two groups in the effect of treating hunger and disdesire(P>0.05).(6)adverse reactions:no adverse reactions were found in the two groups.Conclusion:Jinghua weikang capsule combined with quadruple therapy is superior to Bismuth quadruple therapy in clinical symptom improvement,although it cannot significantly improve the eradication rate and reduce the recurrence rate of Hp.During the study,no adverse events occurred and the safety was good,it provides clinical basis for TCM syndrome differentiation in the treatment of chronic non-atrophic gastritis infected by helicobacter pylori. |
PDF Full Text Request